Based on these results, the phase III HERTHENA-Lung02 trial is investigating the efficacy and safety of HER3-DXd compared with PBC in patients with metastatic or locally advanced NSCLC with a common EGFR-activating mutation after progression with a third-generation EGFR TKI [49]. Here, EGFR is linked to non-small cell lung carcinoma.